STRATA Skin Sciences Inc (SSKN) Expected to Announce Quarterly Sales of $7.64 Million
Equities research analysts forecast that STRATA Skin Sciences Inc (NASDAQ:SSKN) will post $7.64 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for STRATA Skin Sciences’ earnings, with estimates ranging from $7.60 million to $7.67 million. STRATA Skin Sciences reported sales of $7.48 million during the same quarter last year, which indicates a positive year-over-year growth rate of 2.1%. The firm is expected to report its next quarterly earnings report on Thursday, November 8th.
According to Zacks, analysts expect that STRATA Skin Sciences will report full-year sales of $29.70 million for the current financial year, with estimates ranging from $29.40 million to $30.00 million. For the next financial year, analysts expect that the company will report sales of $34.15 million, with estimates ranging from $33.80 million to $34.50 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow STRATA Skin Sciences.
STRATA Skin Sciences (NASDAQ:SSKN) last released its quarterly earnings data on Monday, August 13th. The medical device company reported ($0.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. STRATA Skin Sciences had a negative return on equity of 27.01% and a negative net margin of 63.07%. The business had revenue of $7.53 million for the quarter, compared to analyst estimates of $6.84 million.
Several large investors have recently made changes to their positions in SSKN. Macquarie Group Ltd. lifted its position in shares of STRATA Skin Sciences by 89.7% during the 2nd quarter. Macquarie Group Ltd. now owns 134,033 shares of the medical device company’s stock valued at $275,000 after buying an additional 63,393 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of STRATA Skin Sciences by 164.6% during the 2nd quarter. Renaissance Technologies LLC now owns 293,499 shares of the medical device company’s stock valued at $602,000 after buying an additional 182,579 shares in the last quarter. Menora Mivtachim Holdings LTD. purchased a new position in shares of STRATA Skin Sciences during the 2nd quarter valued at approximately $1,138,000. Finally, Nantahala Capital Management LLC purchased a new position in shares of STRATA Skin Sciences during the 2nd quarter valued at approximately $4,261,000. Hedge funds and other institutional investors own 27.47% of the company’s stock.
STRATA Skin Sciences stock opened at $3.50 on Thursday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.20 and a current ratio of 4.77. STRATA Skin Sciences has a 12 month low of $1.06 and a 12 month high of $3.88. The company has a market capitalization of $109.89 million, a price-to-earnings ratio of 1.76 and a beta of 0.69.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
Further Reading: Why do companies issue stock splits?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.